{
  "version": "https://jsonfeed.org/version/1.1",
  "title": "GI Signals - Pancreas/Biliary",
  "home_page_url": "https://siftingsignal.com/gisignals/",
  "feed_url": "https://siftingsignal.com/gisignals/feed/pancreas-biliary.json",
  "description": "Pancreas/Biliary papers worth knowing in GI this week. A SiftingSignal publication.",
  "items": [
    {
      "id": "https://siftingsignal.com/gisignals/2026-W29/#card-pmid-42442510",
      "url": "https://siftingsignal.com/gisignals/2026-W29/#card-pmid-42442510",
      "title": "Molecular Subtypes of Cholangiocarcinoma and their Translational Implications.",
      "date_published": "2026-07-18T20:04:34Z",
      "content_text": "Gastroenterology. Consider molecular profiling for intrahepatic cholangiocarcinoma patients to identify actionable targets such as fibroblast growth factor receptor 2 fusions and isocitrate dehydrogenase 1 or 2 mutations, which may guide targeted therapy decisions."
    },
    {
      "id": "https://siftingsignal.com/gisignals/2026-W29/#card-pmid-42463583",
      "url": "https://siftingsignal.com/gisignals/2026-W29/#card-pmid-42463583",
      "title": "Neoadjuvant and adjuvant treatment for pancreatic ductal adenocarcinoma in patients over 80 years old based on a nationwide clinical database.",
      "date_published": "2026-07-18T20:04:34Z",
      "content_text": "Journal of gastroenterology. Consider adjuvant therapy for PDAC patients over 80 years old after pancreatectomy, as it significantly improves survival, but assess individual tolerance and comorbidities. Do not routinely recommend neoadjuvant treatment in this age group based on current evidence, though interpret cautiously due to limited resectability-adjusted data."
    },
    {
      "id": "https://siftingsignal.com/gisignals/2026-W26/#card-pmid-41941588",
      "url": "https://siftingsignal.com/gisignals/2026-W26/#card-pmid-41941588",
      "title": "pRECIST: Guidelines for Response Criteria for Use in Trials Testing Therapeutics in Pancreatic Cancer.",
      "date_published": "2026-07-09T16:47:07Z",
      "content_text": "Pancreas. Use pRECIST criteria for consistent response assessment in clinical trials testing pancreatic cancer therapies, particularly in neoadjuvant settings, as it requires CT and PET imaging for combined size and metabolic evaluation."
    },
    {
      "id": "https://siftingsignal.com/gisignals/2026-W26/#card-pmid-42386316",
      "url": "https://siftingsignal.com/gisignals/2026-W26/#card-pmid-42386316",
      "title": "Robotic versus Open Pancreatoduodenectomy (PORTAL): multicentre, single masked, phase 3, non-inferiority randomised controlled trial.",
      "date_published": "2026-07-09T16:47:07Z",
      "content_text": "BMJ (Clinical research ed.). For resectable pancreatic or periampullary disease in eligible patients at high-volume centers, consider robotic pancreatoduodenectomy (RPD) as a non-inferior alternative to open surgery (OPD) for potentially faster recovery and reduced complications."
    },
    {
      "id": "https://siftingsignal.com/gisignals/2026-W26/#card-pmid-42402265",
      "url": "https://siftingsignal.com/gisignals/2026-W26/#card-pmid-42402265",
      "title": "Durvalumab with gemcitabine-based chemotherapy regimens in advanced biliary tract cancer: primary results from the phase IIIb TOURMALINE study.",
      "date_published": "2026-07-09T16:47:07Z",
      "content_text": "Journal of hepatology. Durvalumab added to gemcitabine-based chemotherapy is already standard first-line care for advanced biliary tract cancer (TOPAZ-1); TOURMALINE supports its safety and efficacy across a broader range of gemcitabine-based regimens rather than establishing a new, unadopted therapy."
    }
  ]
}